Information Provided By:
Fly News Breaks for May 3, 2016
PCRX
May 3, 2016 | 07:29 EDT
Brean Capital noted Q1 results for Pacira were seasonally soft, but they expect them to improve in Q2. The firm said Pacira is on track with its progress in two Phase 3 trials, sees a large growth opportunity in spine, and expects sales to accelerate in the second half of 2016. Brean Capital reiterated its Buy rating and $75 price target on Pacira shares.
News For PCRX From the Last 2 Days
There are no results for your query PCRX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.